74 results about "Apigetrin" patented technology

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention provides an apigenin nanoparticle preparation as well as a preparation method and application thereof. The preparation method comprises the following steps: weighing apigenin, dissolving the apigenin in an acetone solution containing a polylactic acid-glycolic acid copolymer, or dissolving the apigenin in an acetone solution containing the polylactic acid-glycolic acid copolymer and Eudragit S100, and uniformly stirring and mixing at room temperature to obtain a mixed solution; dropwise adding the mixed solution into a polyvinyl alcohol solution, carrying out ultrasonic treatment, and removing the solvent to prepare PANPs or PEANPs. The preparation method is simple, and the prepared PANPs and PEANPs are small in particle size and high in encapsulation efficiency, can effectively penetrate through intestinal epithelial barriers and promote internalization of apigenin into cells, have a good slow release characteristic, can remarkably improve the bioavailability of apigenin, and have a good treatment effect on inflammatory bowel diseases. PANPs has a better treatment effect on ulcerative colitis, and PEANPs has a better treatment effect on diffuse colitis.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention discloses radix tetrastigme flavone synthase and application thereof. The radix tetrastigme flavone synthase comprises an amino acid sequence as shown in SEQ ID No. 2. The key enzyme-flavone synthase gene (ThFNS) related to synthesis of apigenin in radix tetrastigme is cloned for the first time, in-vitro recombinant protein expression and enzymatic reaction system verification show that flavone synthase can catalyze naringenin to generate apigenin, and technical support is provided for follow-up metabolic engineering modification for an apigenin biosynthetic pathway.

The invention discloses an apigenin derivative as well as a preparation method and application thereof. The apigenin derivative has the following molecular structure expression, and the preparation method comprises the following steps: 1) in the presence of an optional catalyst, reacting p-coumaric acid with ethyl sulfonyl chloride to generate an intermediate 1; and 2) mixing the purified intermediate 1 with oxalyl chloride for reaction, carrying out acylating chlorination, adding apigenin, and carrying out stirring reaction in the presence of an acid-binding agent to obtain the apigenin derivat.The apigenin derivative is novel in structure and has good biological activity for reducing the blood uric acid level in vivo.

The present invention discloses a golden chrysanthemum flavonoid glycoside derived from golden chrysanthemum, wherein the golden chrysanthemum flavonoid glycoside is apigenin 7-O-(6"-O-malonyl)-β-D-glucoside derived from golden chrysanthemum. The present invention separates and purifies apigenin 7-O-(6"-O-malonyl)-β-D-glucoside from golden chrysanthemum for the first time, completes the first synthesis through a 5-step synthesis process with a total yield of 2.7%, and discovers for the first time that the compound has activity in improving hyperlipidemia and fatty liver in vitro and in vivo. Therefore, the compound can be used in the preparation of products for treating related diseases such as hyperlipidemia and fatty liver.

The invention provides a universal technical method for detecting non-toxic Chinese herbal medicine based on UPLC-QTOF-MS, and relates to the field of traditional Chinese medicine detection and analysis. The method comprises the following steps: S1, crushing non-toxic traditional Chinese medicinal materials; s2, preparing a to-be-detected sample solution; s3, preparing a QC accompanying standard product; s4, carrying out liquid mass analysis on the to-be-detected sample; and S5, processing mass spectrum information data. The method is characterized in that the QC standard substance in the step S3 is one or more of araflavin, aurantio-obtusin, patchouli ketone, apigenin, mangiferin, ginsenoside Rg1 and timosaponin, and chromatography-mass spectrometry conditions are defined in the step S4. The method disclosed by the invention has the advantages that a universal technical method is established instead of aiming at each specific traditional Chinese medicine, and targeted identification and analysis are not solved, so that a unified system is formed by inspection and analysis of different non-toxic Chinese herbal medicines, and non-targeted identification and analysis can be realized according to result differences on the premise of controlling the method differences.

This invention belongs to the field of biomedical technology, and particularly relates to a pharmaceutical composition for treating cervical cancer and its preparation method. The pharmaceutical composition for treating cervical cancer of this invention comprises the following components: a apigenin derivative and acetylvalerin in a mass ratio of 1:(0.3~0.5). This invention obtains a apigenin derivative by introducing specific functional groups onto apigenin, which exhibits high pharmacological activity against cervical cancer; synergistically acting with acetylvalerin, it effectively kills cervical cancer cells while reducing damage to normal cells, thus providing a safer and more effective treatment option for cervical cancer patients.

The invention discloses an apigenin derivative, a preparation method and application of the apigenin derivative in uric acid lowering drugs, the apigenin derivative has a molecular structure expression shown in the specification, and research shows that the apigenin derivative can lower uric acid through the dual effects of generation inhibition and excretion promotion, has no obvious influence on 24-hour urine creatinine and is expected to have good kidney safety.

The invention provides a multi-layer core natural polyphenol algal gel candy for pets with oxidation resistance. The algal gel candy comprises a skin material and a multi-layer core material wrapped in the skin material, the formula of the skin material comprises the following components in parts by weight: 80-90% of algae gel, 1-5% of coconut powder and 0.05-0.1% of potassium sorbate; the core material comprises an inner layer, a middle layer and an outer layer, each layer is prepared by mixing 1-3% of one of apigenin, quercetin and luteolin with 1-5% of coconut powder, and natural polyphenols contained in the inner layer, the middle layer and the outer layer are different from one another; according to the algae gel candy, multiple layers of natural polyphenols are used as core materials to be combined with algae gel used as skin materials, and the gel candy with the functional multiple layers of cores is prepared; the candy has relatively strong antioxidant ability, can effectively remove free radicals in the body and delay senescence so as to improve the immunity of the body, and has a wide market application prospect.

The invention relates to the technical field of plant extraction, in particular to a rose extract. The rose extract comprises at least one of monomer ellagic acid, urolithin M5 and apigenin. The preparation method comprises the following steps: uniformly mixing rose powder with the ternary synergistic solvent, carrying out ultrasonic treatment for 10-60 minutes under the ultrasonic power of 150-250 W, and then stirring for 1-5 hours at the temperature of 20-50 DEG C; centrifuging and collecting supernate to obtain the rose extract. The rose flower extract provided by the invention has relatively strong inhibition capability on human pancreatic lipase.

This invention belongs to the field of pharmaceutical technology and specifically relates to the use of apigenin derivatives in the preparation of anti-tumor drugs. The structure of the apigenin derivative is shown below: wherein the groups are defined as described in the specification. The compounds of this invention effectively inhibit the proliferation of renal cancer Caki-1 cells, human gastric cancer cells SNU-5, lung cancer cells, and human colon cancer cells HCT 116 in vitro. They also exhibit good inhibitory activity against renal cancer Caki-1 cells in vivo, demonstrating promising application prospects.

The application discloses a bacterial QS inhibitor and application thereof, and the active ingredient of the bacterial QS inhibitor is apigenin, and the use concentration is a sub-inhibitory concentration of target bacteria. The application first discovers and systematically proves that apigenin has a wide and significant inhibitory effect on a variety of bacterial QS systems and a spoilage phenotype regulated by the QS systems. Experiments show that under a sub-inhibitory concentration, the inhibition rate of apigenin on biofilm formation of pectobacterium is up to 96.33%, the inhibition rate of apigenin on synthesis of a signal molecule is up to 88.42%, and the inhibition rate of apigenin on a key virulence enzyme is more than 70%; the fresh-keeping effect of apigenin on food is significant, and the application of apigenin in the field of food fresh-keeping is expanded; and apigenin is a natural dietary ingredient and has high safety.

This invention discloses a apigenin-betaine compound and its preparation method. The compound uses apigenin (Api) as its core, with -O-(CH2) at the 7', 4', and / or 5-position hydroxyl groups. n -N + (CH3)2-CH2COO ‑ Fragment substitution (n=2~12, x=1~3) forms an internal salt-type zwitterionic structure. In preparation, apigenin is first reacted with bromool Br(CH2). n A mitsunobu reaction was performed on OH under triphenylphosphine / dialkyl azodicarbonate conditions to obtain mono / polysubstituted bromoalkoxylated apigenin; subsequently, nucleophilic substitution with N,N-dimethylglycine under alkaline conditions yielded the target product. This structure, possessing both a tunable alkyl chain and a betaine cation / anion pair, significantly enhances the solubility and hydration capacity of apigenin in aqueous / alcoholic media, strengthens its affinity and stability for biomembranes, thereby improving in vivo absorption and distribution and potentially maintaining its antioxidant and anti-inflammatory activities. The method is mild, with a wide solvent and temperature range, suitable for scale-up and formulation applications.

The present invention relates to new solid forms (NSF) of a flavonoid and a coformer. The NSF are co-amorphous solids of flavonoids and amino acids, as well as the solvates of said co-amorphous solids. The flavonoid is selected from quercetin, genistein, fisetin, apigenin, naringenin, rutin, diosmin, among others. The coformer is selected from lysine and arginine. The NSF have enhanced stability, solubility and pharmacological properties over parent polyphenols. The new solid forms are suitable to be used in pharmaceutical compositions, food products, nutritional supplements and the like.

The invention discloses a method for performing carbon glycoside deglycosylation by using a biological method. The invention provides application of the protein combination: application in splitting C-C glucosidic bonds; application in preparation of aglycones; the invention also relates to an application in converting glucoside into aglycone. The invention also relates to an application in converting isoorientin and isovitexin into luteolin and apigenin. The invention also relates to an application in converting isoorientin into luteolin. The invention also relates to an application in converting isovitexin into apigenin. Application in splitting C-C glucosidic bonds; the invention also relates to an application in converting mangiferin into mangiferin aglycone. The protein combination comprises an LE1 protein, an LE2 protein and an LE3 protein. The method has great application and popularization values in the production field of aglycones or aglycone derivatives and downstream products thereof.

The invention relates to the field of biological pharmacy, and discloses an application of an FABP5 protein target inhibitor in preparation of a product for treating cancers, and the inhibitor is apigenin 7-O-malonyl glucoside. The invention provides a novel cancer cell targeting therapeutic drug, the inhibitor inhibits proliferation of renal clear cell adenocarcinoma and subcutaneous tumor-bearing through precise targeting of FABP5 protein and can be applied to preparation of anti-renal clear cell adenocarcinoma and subcutaneous tumor-bearing drugs, and apigenin 7-O-malonyl glucoside can be used in combination with a PD-1 monoclonal antibody, so that the treatment effect is good. The inhibition effect is better, and a new treatment scheme is provided for the treatment of the kidney cancer.

The invention relates to the technical field of component detection of clerodendrum japonicum, in particular to a method for determining the content of active substances in clerodendrum japonicum based on a high performance liquid chromatography method. The invention provides a method for determining the content of active substances in clerodendrum japonicum based on high performance liquid chromatography, which comprises the following steps: (1) mixing the clerodendrum japonicum medicinal material with ethanol, and carrying out ultrasonic treatment to obtain a test solution; the method comprises the following steps: respectively taking a chlorogenic acid solution, an apigenin-7-O-diglucuronic acid solution, a verbascoside solution and an acacetin-7-O-[beta-D-glucopyranuronyl (1-> 2)-O-D-glucopyranuronide] solution as reference substance solutions; and (2) performing high performance liquid chromatography detection on the test solution and the reference solution obtained in the step (1). The method can be used for simultaneously detecting the contents of four active components in clerodendrum japonicum, is low in detection limit and wide in linear range, and ensures the accuracy and reliability of a detection result.

The application discloses a kind of high-efficiency interception polyvalent anion and cation nanofiltration membrane and its preparation method and application.The method includes the following preparation process:1) preparation concentration is 0.1-2wt% of apigenin class of substance aqueous solution, and concentration is 0.1-0.5wt% of multi-acid chloride organic phase solution;2) make polymer support membrane in aqueous solution 1-5min, remove the surface excess solution, then immerse into oil phase solution, react 1-15min;3) after reaction, remove the surface excess solution, solidify 5-20min under 60-80 DEG C, obtain the nanofiltration membrane.The application is with apigenin, apigenin-7-o-glucuronide and / or isofraxidin as aqueous monomer, and multi-acid chloride is prepared by interfacial polymerization reaction to obtain negative NF membrane, not only maintain the high interception rate to polyvalent anion, and also have very high interception rate to polyvalent cation, can efficiently permeate monovalent ion, and water flux is larger.

The invention provides a construction method and application of a specific chromatogram of Pinger honey cream. The construction method comprises the following steps: a) preparation of a reference substance solution: respectively adding methanol to dissolve caffeic acid, linarin, luteolin and apigenin as reference substances to obtain the reference substance solution; b) preparation of a test solution: mixing the Pinger honey paste with a methanol solution, performing heating reflux treatment or ultrasonic treatment, cooling, and filtering to obtain the test solution; and c) determining to obtain a high performance liquid chromatogram of the test solution and a high performance liquid chromatogram of the reference solution, and selecting a common peak from the high performance liquid chromatogram of the test solution by taking the high performance liquid chromatogram of the reference solution as a contrast to obtain the characteristic chromatogram of the Pinger honey cream. By adopting the method, the specific chromatogram of the Pinger honey cream can be obtained to characterize the quality of the Pinger honey cream, so that the stability of the medicinal materials is better evaluated, and a quality evaluation system of the Pinger honey cream is perfected.

The invention discloses application of apigenin-7-O-glucuronide in preparation of a medicine for treating coronavirus, and belongs to the technical field of pharmacology of traditional Chinese medicines. The application comprises the application of the apigenin-7-O-glucuronide serving as the RIG-I protein agonist and the application of the apigenin-7-O-glucuronide in preparation of the medicine for treating the coronavirus. Experiments prove that the apigenin-7-O-glucuronide has a good inhibition effect on the coronavirus by being used as the RIG-I protein agonist, and an experimental basis is provided for the apigenin-7-O-glucuronide to prevent and treat the coronavirus infection.

The invention belongs to the technical field of natural medicine extracts, and relates to a polygonatum sibiricum flower bud extract as well as a preparation method, a microcapsule preparation and application thereof. The polygonatum sibiricum flower bud extract contains one or more of rutin, apigenin-6-arabinose-8-glucoside, and apigenin-6, 8-diglucoside, and is characterized in that the polygonatum sibiricum flower bud extract contains one or more of rutin, apigenin-6-arabinose-8-glucoside and apigenin-6, 8-diglucoside. By utilizing the preparation method of the polygonatum sibiricum flower bud extract and the preparation method of the microcapsule preparation, the polygonatum sibiricum flower bud extract and the microcapsule preparation of the polygonatum sibiricum flower bud extract can be better prepared respectively; the prepared polygonatum sibiricum flower bud extract and the microcapsule preparation of the polygonatum sibiricum flower bud extract can better inhibit the activity of alpha-glucosidase in vivo and in vitro, and can be used for preventing or treating diabetes mellitus with better curative effect and smaller side effect.

The invention discloses a tetrastigma hemsleyanum C-glycosyl transferase and application thereof. The amino acid sequence of the C-glycosyl transferase comprises a sequence as shown in SEQ ID NO. 4. The key enzyme-glycosyltransferase (ThCGT) related to vitexin synthesis in radix tetrastigme is cloned for the first time, and it is verified through in-vitro experiments that the enzyme can efficiently catalyze apigenin C-8 site glycosylation reaction to generate vitexin. Furthermore, according to the invention, a tobacco transient expression system is utilized to confirm that the enzyme can also glycosylate the apigenin C-8 site in a plant body to generate vitexin. Besides, a tobacco stable expression system capable of efficiently generating vitexin is further constructed, and an efficient platform is provided for large-scale production of vitexin, so that the production cost of vitexin is expected to be reduced, the market supply is expected to be improved, and a basis is provided for wide application of vitexin in the fields of medicines, health care products, cosmetics and the like.

The application belongs to the field of medicine and organic synthesis, and relates to an apioin derivative, a preparation method and application thereof, a structural formula of the apioin derivative is as follows: wherein R is or the apioin derivative provided by the application has excellent inhibitory effect on xanthine oxidase, and can be applied to the preparation of a drug with xanthine oxidase as a target. The application provides a potential selection for the research and development of a drug for treating hyperuricemia.

The invention belongs to the technical field of active component and target screening, and relates to a purple sweet potato leaf uric acid reducing active component and a potential target and a screening method thereof, the active component comprises rhododendron yellow, 3, 4, 2 ', 4', 6 '-pentahydroxychalcone, apigenin, quercetin glycoside, 6-hydroxycoumarin, 6, 6-dihydroxycoumarin, 3, 4, 2', 4 ', 6'-pentahydroxychalcone, 3, 4, 2 ', 4', 6 '-pentahydroxychalcone, 3, 4, 2', 4 '-pentahydroxychalcone, the component A is prepared from 2, 7-dihydroxy coumarin, daphnetin, trigonelline, serotonin, salidroside, sesamin and nicotinamide; the potential target spots comprise INS, PPAR-gamma, IL1-beta, PPAR-alpha, XDH and ABCG2; the method comprises the following steps: preparing purple sweet potato leaves and a sweet potato leaf water extract, determining the uric acid generation inhibition activity of the purple sweet potato leaves through an in-vitro experiment, and carrying out differential metabonomics combined network pharmacology analysis to excavate functional substances for reducing uric acid in the purple sweet potato leaves, thereby providing a material basis for high-valued utilization of the purple sweet potato leaves and development of functional foods for reducing uric acid.

This invention discloses a method for preparing an oral nanoparticle formulation of apigenin, belonging to the field of traditional Chinese medicine preparation technology. The method uses a mixture of soybean protein and xylan as the aqueous phase and an apigenin ethanol solution as the organic phase. Nanoparticles are prepared by antisolvent precipitation, followed by adsorption of tannic acid to obtain the final product. The nanoparticles prepared by this invention have a particle size of less than 600 nm and a high encapsulation efficiency. Utilizing the synergistic effect of soybean protein, xylan, and tannic acid, apigenin is protected from gastric acid degradation, achieving targeted intestinal delivery and significantly improving its oral bioavailability. This method can be used to prepare drugs for treating intestinal diseases such as inflammatory bowel disease, irritable bowel syndrome, or colorectal cancer.

The application relates to preparation and application of modified whey protein, especially showing good embedding effect in embedding apigenin. The steps of the preparation method are as follows: (1) 49 mL of deionized water is used to dissolve 0.5 g of whey protein in a beaker, 1 mL of 5M hydrogen peroxide solution which has been prepared is added into the beaker after the protein is fully dissolved, 0.25 g of ascorbic acid is weighed and added, uniform mixing is carried out, and then the mixture is placed at room temperature for 2 h. (2) 0.35 mM of EGCG and 1 mM of CaCl2 are added into the protein solution after 2 h, the polyphenol and CaCl2 are stirred to be dissolved, and then the solution is placed at room temperature for reaction for 24 h. (3) after the reaction is completed, the solution after the reaction is dialyzed by using a 3500D dialysis bag to remove the polyphenol which is not combined on the protein, and the solution is dialyzed at 4 DEG C for 48 h, and the dialysis liquid is replaced every 6 h. 2+ The grafting rate of WP-EGCG is improved, the functional properties of the whey protein are enhanced, and the embedding rate of apigenin is preferably improved.

This invention discloses a diglyceride-based edible oil for assisting in lowering uric acid and its preparation method, relating to the field of edible oil technology. This diglyceride-based edible oil for assisting in lowering uric acid comprises the following ingredients in parts by weight: 42-50 parts modified high-oleic sunflower seed oil, 8-12 parts food-grade glycerol, 1.5-2.5 parts immobilized Rhizopus oryzae lipase, 0.3-0.8 parts modified apigenin, 0.2-0.4 parts vitamin E, 0.3-0.5 parts monoglyceride citrate, and 1.0-1.5 parts hydroxytyrosol. This composite edible oil combines the health benefits of diglycerides with the function of assisting in lowering uric acid. It exhibits good compatibility and stability of active ingredients, high bioavailability, excellent physicochemical properties, suitability for various cooking methods, and easy storage.

The present invention discloses an apigenin derivative, a solvate or pharmaceutically acceptable salt thereof, and its use in the preparation of a uric acid-lowering drug, belonging to the field of pharmaceutical technology. The apigenin derivative of the present invention, having a structure represented by formula (I), is prepared by grafting apigenin onto carnosine. The compound of formula (I) exhibits superior uric acid-lowering effects compared to the raw materials apigenin and carnosine, as well as the traditional positive drug benzbromarone, which also have the effect of lowering blood uric acid.